CASPAR, NCT04940039: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings |
|
|
| Completed | 4 | 93 | RoW | Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., R092670, Paliperidone Palmitate 75 mg eq., Paliperidone Palmitate 100 mg eq., Paliperidone Palmitate 150 mg eq., Paliperidone Palmitate 175 mg eq., Paliperidone Palmitate 263 mg eq., Paliperidone Palmitate 350 mg eq., Paliperidone Palmitate 525 mg eq. | Janssen-Cilag International NV | Schizophrenia | 04/24 | 04/24 | | |
NCT02772393 / 2015-004835-10: A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation |
|
|
| Recruiting | 3 | 300 | Europe, RoW | Paliperidone palmitate 3 month formulation (PP3M) | Janssen-Cilag Ltd., Janssen-Cilag International NV | Schizophrenia | 12/17 | 03/18 | | |
| Recruiting | 2/3 | 240 | RoW | Aripiprazole, Paliperidone, Treatment as Usual | The University of Hong Kong, Queen Mary Hospital, Hong Kong, North District Hospital | Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy | 05/24 | 05/25 | | |